SMS Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Pharmaceuticals reported strong FY25 results with standalone revenue from operations rising to Rs. 78,274.81 lakhs from Rs. 70,926.34 lakhs in FY24, a growth of about 10.4%. Net profit jumped to Rs. 6,838.12 lakhs from Rs. 4,942.49 lakhs, a 38% YoY increase, while EPS climbed to Rs. 8.07 from Rs. 5.84. Q4 standalone profit rose to Rs. 2,062.24 lakhs from Rs. 1,592.18 lakhs a year ago. The statutory auditors (Suryanarayana & Suresh) issued an unmodified (clean) opinion on both standalone and consolidated results. The board recommended a final dividend of 40% (Re. 0.40 per share) for FY25, subject to shareholder approval.
Strong profit growth and an improved operating margin signal healthy business momentum, while the 40% dividend rewards shareholders. The clean audit opinion and continued capacity investment (new greenfield subsidiary and Rs. 10 Cr infusion into SMS Peptides) suggest management confidence, though debt levels have risen modestly.